Gc Cell Corporation

Sungyoo Cho

Jong Seo Lee

Kyu Tae Kim

Jeongmin Kim

Bong Kook Ko

In Sik Hwang

Young Ha Lee

Miyoung Jung

You-Sun Kim

Eunji Choi

Hoyong Lim

Yu Kyeong Hwang

Bokyung Min

Bitna Yang

Eun Ji Kim

Yusun Kim

Gyeong-min Park

The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds.

Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same

The present invention relates to a method for culturing cord blood-derived natural killer cells using transformed T cells. The method of the present invention uses transformed T cells to culture natural killer cells and enables effective proliferation and production of natural killer cells from a small amount of seed cells. In addition, natural killer cells produced by the method of the present invention have improved cytotoxicity. Therefore, the method of the present invention is useful in commercializing natural killer cells for cell therapy. Furthermore, natural killer cells produced by the method of the present invention are useful for cell therapy.

Method for culturing cord blood-derived natural killer cells using transformed T-cells

Growing community of inventors

Yongin-si, South Korea

Sungyoo Cho